Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Urology

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EURURO.2007.10.017PMID 17964070
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development and external validation of an extended 10-core biopsy nomogram.

  2007cited by this paper
• Screening for prostate cancer at low PSA range: The impact of digital rectal examination on tumor incidence and tumor characteristics

  2007cited by this paper
• Prostate volume measured preoperatively predicts for organ-confined disease in men with clinically localized prostate cancer.

  2007cited by this paper
• Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.

  2007cited by this paper
• Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.

  2007cited by this paper
• Different prostate‐specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies

  2007cited by this paper
• Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.

  2006cited by this paper
• Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.

  2006cited by this paper
• Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

  2006cited by this paper
• Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study.

  2005cited by this paper
• Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen.

  2005cited by this paper
• Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.

  2005cited by this paper
• Hepatic resection: the last surgical frontier for colorectal cancer.

  2005cited by this paper
• Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

  2005cited by this paper
• Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

  2004cited by this paper
• Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen.

  2003cited by this paper
• EAU guidelines on prostate cancer.

  2001cited by this paper
• Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?

  2001cited by this paper
• Prostate cancer detection at low prostate specific antigen.

  2000cited by this paper
• Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

  1999cited by this paper
• Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.

  1998cited by this paper
• Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer

  1998cited by this paper
• Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

  1997cited by this paper
• A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.

  1995cited by this paper
• Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.

  1991cited by this paper

• 3D-AttenNet model can predict clinically significant prostate cancer in PI-RADS category 3 patients: a retrospective multicenter study

  2025cites this paper
• Age-specific percentile-based prostate-specific antigen cutoff values predict the risk of prostate cancer: A single hospital observation

  2023influential citation
• Ultrasensitive Electrochemical Immunosensors Using Nanobodies as Biocompatible Sniffer Tools of Agricultural Contaminants and Human Disease Biomarkers

  2023cites this paper
• Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators

  2023cites this paper
• Automated Ki‐67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry

  2023cites this paper
• Urine Cell-Free MicroRNAs in Localized Prostate Cancer Patients

  2022cites this paper
• Machine learning model for the prediction of prostate cancer in patients with low prostate-specific antigen levels: A multicenter retrospective analysis

  2022cites this paper
• Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy

  2021cites this paper
• Development of a Sol-gel-assisted Reverse-phase Microarray Platform for Simple and Rapid Detection of Prostate-specific Antigen from Serum

  2018cites this paper
• Risk score predicts high‐grade prostate cancer in DNA‐methylation positive, histopathologically negative biopsies

  2016cites this paper
• Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.

  2016cites this paper
• HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy

  2015cites this paper
• Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence‑specific RNA capture.

  2015cites this paper
• Prevalence of high-grade or insignificant prostate cancer in Korean men with prostate-specific antigen levels of 3.0-4.0 ng/mL.

  2015cites this paper
• Das Niedrig-Risiko-Prostatakarzinom – Strategien zur Reduktion von Überdiagnose und Übertherapie

  2015cites this paper
• Indications for Initial Biopsy: Is the PSA Threshold ERA Over?

  2013cites this paper
• Editorial Comment to Population screening for prostate cancer: An overview of available studies and meta‐analysis

  2012cites this paper
• Focal Therapy: Prostate Hemiablation as the First Historical Treatment Model for Focal Therapy of Early Stage Prostate Cancer

  2012cites this paper
• An overview of prostate diseases and their characteristics specific to Asian men.

  2012cites this paper
• Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer.

  2012cites this paper
• REZUMATUL TEZEI DE DOCTORAT

  2011cites this paper
• Is there an optimal prostate-specific antigen threshold for prostate biopsy?

  2011cites this paper
• Prostate Volume and Its Correlation with Histopathological Outcomes in Prostate Cancer

  2011cites this paper
• Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study.

  2010cites this paper
• Innovative biomarkers for prostate cancer early diagnosis and progression.

  2010cites this paper
• Prostatectomía radical, resultados quirúrgico-oncológicos; siete años de experiencia en el Hospital General de Occidente

  2010cites this paper
• Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer

  2009cites this paper
• ETS gene fusions in prostate cancer: from discovery to daily clinical practice.

  2009cites this paper
• Technologies for localization and diagnosis of prostate cancer

  2009cites this paper
• Percent free prostate‐specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower

  2008cites this paper
• Prostate cancer in men with serum PSA of <4 ng/ml: under-diagnosed or over-treated?

  2008cites this paper
• Current prostate cancer: 20 years later

  2007cites this paper
• Different prostate‐specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies

  2007cites this paper